Honestly when Bot said they were entering into labeling discussions I thought they would be signed off on approved and the name etc…. Would be ok ready for approval if granted. I struggle to see how an organization that is providing review and oversight can’t get their end right. They should provide feedback until everyone is happy. FDA should not have held up approval and provided clearer instructions and labeling should have been finalized.
Ann: Presentation- FDA Letter Requires Patient Instruction Update, page-58
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $669.7M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 400 | 2 |
View Market Depth
| Last trade - 09.35am 15/08/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
Day chart unavailable